Elevance Health (ELV) Stock Price, News & Analysis

Company Overview

Elevance Health, Inc. (NYSE: ELV), formerly known as Anthem, Inc., is a leading health benefits company headquartered in Indianapolis, Indiana. The company operates through its affiliated health plans to offer a range of medical, pharmacy, dental, vision and other complementary benefits to individuals, employers, Medicaid and Medicare members. Elevance Health’s portfolio includes fully insured and self-funded plans, and it leverages partnerships with health systems and care providers to deliver coordinated care and wellness programs.

Central to Elevance Health’s services is its focus on leveraging data analytics and digital platforms to improve member engagement and health outcomes. The company’s IngenioRx pharmacy benefits manager provides prescription drug solutions, while its Value-Based Products and Partnerships segment aligns incentives with providers to manage costs and enhance quality of care. Elevance Health also offers telehealth services, care management, and population health programs designed to address chronic conditions and preventive care needs.

With operations spanning all 50 states and the District of Columbia, Elevance Health serves tens of millions of members through its affiliated Blue Cross and Blue Shield licensees. The company maintains strategic relationships with community health centers and local providers to ensure access to care in urban and rural markets alike. Elevance Health also supports various community initiatives focused on health equity, behavioral health, and social determinants of health.

Elevance Health is led by President and Chief Executive Officer Gail Boudreaux, who joined the company in 2017. Under her leadership, the company has pursued a transformation strategy aimed at enhancing consumer experience, modernizing technology infrastructure, and expanding value-based care arrangements. Elevance Health’s board of directors and executive team bring extensive experience in healthcare administration, finance and public policy, guiding the company as it navigates a dynamic regulatory environment and evolving industry trends.

Key Stats

• Today's Range: $310.45 to $320.10
• 50-Day Range: $274.10 to $395.76
• 52-Week Range: $273.71 to $567.26
• Volume: 3.12 million shs
• Average Volume: 2.24 million shs
• Market Capitalization: $71.83 billion
• P/E Ratio: 13.57
• Dividend Yield: 2.14%
• Price Target: $413.81
• Consensus Rating: Moderate Buy

Elevance Health Stock Analysis - MarketRank™

Elevance Health scored higher than 97% of companies evaluated by MarketBeat, and ranked 45th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elevance Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 12 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Elevance Health has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.99%

Earnings Growth

Earnings for Elevance Health are expected to grow by 14.99% in the coming year, from $33.96 to $39.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elevance Health is 13.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elevance Health is 13.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.27.

Price to Earnings Growth Ratio

Elevance Health has a PEG Ratio of 1.17. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Elevance Health has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.26% of the float of Elevance Health has been sold short.

Short Interest Ratio / Days to Cover

Elevance Health has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elevance Health has recently increased by 4.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Elevance Health pays a meaningful dividend of 2.20%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Elevance Health has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Elevance Health is 29.11%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Elevance Health will have a dividend payout ratio of 17.52% next year. This indicates that Elevance Health will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.26% of the float of Elevance Health has been sold short.

Short Interest Ratio / Days to Cover

Elevance Health has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elevance Health has recently increased by 4.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.54

News Sentiment

Elevance Health has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Elevance Health this week, compared to 43 articles on an average week.

Search Interest

43 people have searched for ELV on MarketBeat in the last 30 days. This is an increase of 2% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Elevance Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Elevance Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,813,570.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.29% of the stock of Elevance Health is held by insiders.

Percentage Held by Institutions

89.24% of the stock of Elevance Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELV Stock Analysis - Frequently Asked Questions

How have ELV shares performed this year?

Elevance Health's stock was trading at $368.90 on January 1st, 2025. Since then, ELV shares have decreased by 13.5% and is now trading at $318.9980.

How were Elevance Health's earnings last quarter?

Elevance Health, Inc. (NYSE:ELV) posted its quarterly earnings data on Thursday, July, 17th. The company reported $8.84 earnings per share for the quarter, missing analysts' consensus estimates of $9.30 by $0.46. The company's revenue for the quarter was up 14.3% on a year-over-year basis.
Read the conference call transcript.

Does Elevance Health have any subsidiaries?

Elevance Health subsidiaries include these companies: Beacon Health Options, Aspire Healthcare Corp, America’s 1st Choice, HealthSun Health Plans, Simply Healthcare Holdings, Amerigroup, 1-800 Contacts, and more.

Who are Elevance Health's major shareholders?

Top institutional shareholders of Elevance Health include Vanguard Group Inc. (10.15%), State Street Corp (4.69%), Sanders Capital LLC (2.59%) and Geode Capital Management LLC (2.26%). Insiders that own company stock include Gail Boudreaux, Gloria M Mccarthy, Felicia F Norwood, Charles Morgan Kendrick Jr, Robert L Dixon Jr, Ramiro G Peru, Susan D Devore and Ronald W Penczek.
View institutional ownership trends.

How do I buy shares of Elevance Health?

Shares of ELV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elevance Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevance Health investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Record date for 6/25 Dividend: 6/10/2025
• Ex-Dividend for 6/25 Dividend: 6/10/2025
• Dividend Payable: 6/25/2025
• Last Earnings: 7/17/2025
• Today: 8/31/2025
• Record date for 9/25 Dividend: 9/10/2025
• Ex-Dividend for 9/25 Dividend: 9/10/2025
• Dividend Payable: 9/25/2025
• Next Earnings (Estimated): 10/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Managed Health Care
• Current Symbol: NYSE:ELV
• CIK: 1156039
• Web: www.antheminc.com
• Phone: (800) 331-1476
• Fax: 317-488-6275
• Employees: 104,200
• Year Founded: 1944

Price Target and Rating

• Average Price Target for Elevance Health: $413.81
• High Price Target: $505.00
• Low Price Target: $297.00
• Potential Upside/Downside: +29.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): $23.50
• Trailing P/E Ratio: 13.57
• Forward P/E Ratio: 9.39
• P/E Growth: 1.17
• Net Income: $5.98 billion
• Net Margins: 2.83%
• Pretax Margin: 3.74%
• Return on Equity: 17.59%
• Return on Assets: 6.36%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.44
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $189.25 billion
• Price / Sales: 0.38
• Cash Flow: $39.24 per share
• Price / Cash Flow: 8.13
• Book Value: $194.74 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 225,178,000
• Free Float: 224,525,000
• Market Cap: $71.83 billion
• Optionable: Optionable
• Beta: 0.58